| 1 |
Article Health-related quality of life in juvenile-onset systemic lupus erythematosus and its relationship to disease activity and damage. free! 2004
Ruperto N, Buratti S, Duarte-Salazar C, Pistorio A, Reiff A, Bernstein B, Maldonado-Velázquez MR, Beristain-Manterola R, Maeno N, Takei S, Falcini F, Lepore L, Spencer CH, Pratsidou-Gertsi P, Martini A, Ravelli A. · Università di Genova, Istituto di Ricovero e Cura a Carattere Scientifico G. Gaslini, Genoa, Italy. · Arthritis Rheum. · Pubmed #15188334 links to free full text
Abstract: OBJECTIVE: To assess the health-related quality of life (HRQL) of patients with juvenile-onset systemic lupus erythematosus (JSLE) and its relationship with disease activity and accumulated damage. METHODS: In this cross-sectional study, HRQL was assessed using the Child Health Questionnaire (CHQ), disease activity using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and accumulated damage using the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). RESULTS: A total of 297 patients were included. The mean +/- SD physical and psychosocial summary scores of the CHQ were 40.2 +/- 15.0 and 44.8 +/- 10.7, respectively. The most impaired CHQ subscales were global health, general health perceptions, and parent impact-emotional. The SLEDAI score was significantly correlated with both the physical summary score (r = -0.29, P < 0.0001) and psychosocial summary score (r = -0.25, P < 0.0001), whereas the SDI score was significantly correlated only with the physical summary score (r = -0.23, P = 0.0001). CONCLUSION: We found that patients with JSLE have significant impairment of their HRQL, particularly in the physical domain. HRQL may be affected by both disease activity and accumulated damage, particularly in the renal, central nervous, and musculoskeletal systems.
|
| 2 |
Article Methotrexate as a possible trigger of macrophage activation syndrome in systemic juvenile idiopathic arthritis. 2001
Ravelli A, Caria MC, Buratti S, Malattia C, Temporini F, Martini A. · Dipartimento di Scienze Pediatriche, Università di Pavia, Istituto di Ricovero e Cura a Carattere Scientifico S. Matteo, Italy. · J Rheumatol. · Pubmed #11327264 No free full text.
Abstract: Macrophage activation syndrome (MAS) is a potentially life threatening complication of chronic rheumatic diseases, particularly systemic juvenile idiopathic arthritis (JIA). A number of triggers have been related to the development of MAS, including viral infections, nonsteroidal antiinflammatory drug therapy, and gold salt injections. We describe a patient with systemic JIA who developed MAS shortly after receiving methotrexate, suggesting that this drug can be regarded as a potential trigger of MAS in children with JIA.
|